header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

RESTORATION OF PERIPROSTHETIC OSTEOLYSIS BY SYSTEMIC ALENDRONATE TREATMENT



Abstract

Alendronate is a potent inhibitor of bone resorptive activity, and has been shown to prevent and restore periprosthetic osteolysis in experimental models. A preliminary study was conducted to examine clinical usefulness of a lendronate treatment.

Twenty-five patients (27 hips) with radiological evidence of osteolysis after cemented total hip arthroplasty were included. Of these, 14 patients (15 hips) were administered 5 mg of alendronate daily (alendronate group), and 11 patients (12 hips) did not receive alendronate treatment (control group). The subjects were followed up for 12 months, using radiological examinations and biochemical markers. The radiological analysis was evaluated blindly by 2 joint arthroplasty experts, each with more than 10 years of experience, without knowledge of alendronate administration.

In the alendronate group, average serum bone alkaline phosphatase and urinary excretion of the N-telopep-tide of type I collagen values decreased from the baseline values after administration of alendronate, to 71% and 76% of baseline at the 3-month examination, and 57% and 62% at the 1-year examination, respectively. In the control group, expansion of osteolysis was found in 5 hips (42%) and no hip showed restoration of osteolysis. In the alendronate group, expansion of osteolysiswas found in 2 hips (13%), and restoration of osteolysis was found in 5 hips (33%). There was a statistically significant difference in ratio of hips with osteolysis restoration between the 2 groups (p< 0.05). In the alendronate group, there was no significant difference in age, average linear wear rate of polyethylene, and the biochemical markers, between the hips with and without diminishment of osteolysis.

Conclusions: The present results indicate that clinicala-lendronate treatment can prevent and restore periprosthetic osteolysis, which is generally thought to require surgical intervention. These findings warrant further study of the effects of duration and dose of alendronate treatment, component materials, and component fixation methods.

Correspondence should be addressed to Richard Komistek, PhD, International Society for Technology in Arthroplasty, PO Box 6564, Auburn, CA 95604, USA. E-mail: ista@pacbell.net